Metagenomi Gets FDA Clearance for MGX-001 Trial
The clearance enables initiation of a Phase 1/2 trial of MGX-001 in patients with hemophilia A. The company also reported third-quarter 2026 financial results.
FDA clearance enables initiation of a first-in-human Phase 1/2 trial of MGX-001 in patients with hemophilia AMGX-001 is designed to deliver durable, endogenous Factor VIII (FVIII) activity from a one-time treatment for adults and childrenCompany plans to initiate the INTEGR8 clinical trial in the f…